|
Analytical Challenges in Quantifier Ion Selection Due to Mass Error Variability
|
|
7
|
245
|
July 2, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
9
|
701
|
June 29, 2026
|
|
NDSRI growth with respect to age
|
|
12
|
542
|
June 25, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
3
|
275
|
June 25, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
238
|
June 19, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
22
|
5475
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
142
|
June 16, 2026
|
|
Finasteride NDSRI
|
|
2
|
161
|
June 15, 2026
|
|
Complex versus simple N-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigms -Pub
|
|
7
|
558
|
June 3, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
367
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
272
|
June 1, 2026
|
|
Solution stability of NDSRI
|
|
8
|
376
|
May 25, 2026
|
|
Nitrite in Amines
|
|
15
|
935
|
May 21, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
97
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2870
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
91
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
118
|
May 20, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1106
|
May 18, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
379
|
May 13, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
180
|
May 8, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
168
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
497
|
April 30, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
130
|
April 29, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
472
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
212
|
April 20, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
217
|
April 17, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
126
|
April 14, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
129
|
March 27, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
83
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
343
|
March 19, 2026
|